Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28396735
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Clin+Kidney+J
2017 ; 10
(2
): 188-191
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Clinical proteomics in kidney disease as an exponential technology: heading
towards the disruptive phase
#MMPMID28396735
Sanchez-Niņo MD
; Sanz AB
; Ramos AM
; Fernandez-Fernandez B
; Ortiz A
Clin Kidney J
2017[Apr]; 10
(2
): 188-191
PMID28396735
show ga
Exponential technologies double in power or processing speed every year, whereas
their cost halves. Deception and disruption are two key stages in the development
of exponential technologies. Deception occurs when, after initial introduction,
technologies are dismissed as irrelevant, while they continue to progress,
perhaps not as fast or with so many immediate practical applications as initially
thought. Twenty years after the first publications, clinical proteomics is still
not available in most hospitals and some clinicians have felt deception at
unfulfilled promises. However, there are indications that clinical proteomics may
be entering the disruptive phase, where, once refined, technologies disrupt
established industries or procedures. In this regard, recent manuscripts in CKJ
illustrate how proteomics is entering the clinical realm, with applications
ranging from the identification of amyloid proteins in the pathology lab, to a
new generation of urinary biomarkers for chronic kidney disease (CKD) assessment
and outcome prediction. Indeed, one such panel of urinary peptidomics biomarkers,
CKD273, recently received a Food and Drug Administration letter of support, the
first ever in the CKD field. In addition, a must-read resource providing
information on kidney disease-related proteomics and systems biology databases
and how to access and use them in clinical decision-making was also recently
published in CKJ.